Scynexis Inc
$ 0.79
2.18%
24 Feb - close price
- Market Cap 32,317,300 USD
- Current Price $ 0.79
- High / Low $ 0.82 / 0.77
- Stock P/E N/A
- Book Value 0.87
- EPS -0.51
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.53 %
- 52 Week High 1.31
- 52 Week Low 0.56
About
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Analyst Target Price
$3.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-13 | 2025-05-06 | 2025-03-26 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-07 | 2023-11-13 | 2023-08-14 | 2023-05-10 | 2023-03-31 |
| Reported EPS | -0.17 | -0.14 | -0.11 | -0.09 | -0.06 | -0.3 | 0.01 | -0.39 | -0.04 | 2.46 | -0.71 | -0.37 |
| Estimated EPS | -0.2 | -0.2 | -0.2 | -0.02 | -0.07 | -0.2 | -0.2 | -0.2 | -0.15 | 1.55 | -0.28 | -0.44 |
| Surprise | 0.03 | 0.06 | 0.09 | -0.07 | 0.01 | -0.1 | 0.21 | -0.19 | 0.11 | 0.91 | -0.43 | 0.07 |
| Surprise Percentage | 15% | 30% | 45% | -350% | 14.2857% | -50% | 105% | -95% | 73.3333% | 58.7097% | -153.5714% | 15.9091% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCYX
2026-01-29 09:02:32
SCYNEXIS announced presentations on its second-generation fungerp, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) held in Las Vegas from January 28–30, 2026. The company highlighted SCY-247's potent in vitro and in vivo antifungal activity, favorable safety profile, and supportive pharmacokinetics, positioning it as a potential treatment for drug-resistant fungal infections. This follows recent FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for SCY-247.
2026-01-29 08:59:36
SCYNEXIS, Inc. will present data on its second-generation fungerp drug candidate, SCY-247, at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI). The presentations will highlight SCY-247's potent antifungal activity against drug-resistant fungi, along with its favorable safety profile and pharmacokinetics observed in clinical investigations. This underscores its potential as a critical new agent in combating deadly fungal infections.
2026-01-28 13:31:02
SCYNEXIS, Inc. announced presentations at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) featuring data on their second-generation fungerp drug candidate, SCY-247. The presentations will highlight SCY-247's potent antifungal activity against resistant fungi and its favorable safety profile, positioning it as a critical weapon against deadly fungal infections. This participation underscores SCYNEXIS's commitment to addressing the growing threat of antimicrobial resistance.
2026-01-24 10:28:19
SCYNEXIS (NASDAQ:SCYX) is highlighted as a potentially risky investment due to its significant cash burn relative to its market capitalization and declining operating revenue. While it had a 14-month cash runway as of September 2025, its cash burn increased by 54% in the last year, and revenue decreased by 66%. The analysis indicates a high risk of funding distress, suggesting investors should be cautious.
2026-01-22 10:57:53
SCYNEXIS, Inc. has received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the FDA for its investigational antifungal drug, SCY-247, intended to combat life-threatening resistant fungal infections. These designations reflect the drug's potential, supported by promising preclinical and Phase 1 data, to address the growing public health threat posed by multi-drug resistant fungi like Candida auris. The company plans to initiate Phase 1 and Phase 2 studies for SCY-247 in 2026.
2026-01-21 13:28:14
SCYNEXIS (NASDAQ: SCYX) has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for its investigational antifungal, SCY-247. These designations grant the drug at least 10 years of market exclusivity post-approval and facilitate more frequent FDA interactions and potential accelerated review, recognizing its potential against serious infections like multi-drug resistant Candida auris. The company plans to initiate Phase 1 IV and Phase 2 oral studies in 2026, aiming for oral proof-of-concept data the same year.
